Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00KEF
|
|||
| Former ID |
DIB011416
|
|||
| Drug Name |
Org-2766
|
|||
| Synonyms |
Org-2766; H-Met(O2)-Glu-His-Phe-D-Lys-Phe-OH; UNII-OP1H5I4TBQ; OP1H5I4TBQ; 50913-82-1; AC1OCEIT; (4S)-5-[[(2S)-1-[[(2S)-1-[[(2R)-6-amino-1-[[(2S)-1-hydroxy-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-4-[[(2S)-2-amino-4-methylsulfonylbutanoyl]amino]-5-oxopentanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cognitive impairment [ICD-11: 6D71; ICD-10: F06.7] | Discontinued in Phase 3 | [1] | |
| Company |
Organon BioSciences
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C40H55N9O11S
|
|||
| Canonical SMILES |
CS(=O)(=O)CCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CN=CN1)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CCCCN)C(=O)NC(CC3=CC=CC=C3)C(=O)O)N
|
|||
| InChI |
1S/C40H55N9O11S/c1-61(59,60)19-17-28(42)35(52)45-30(15-16-34(50)51)37(54)48-32(22-27-23-43-24-44-27)39(56)47-31(20-25-10-4-2-5-11-25)38(55)46-29(14-8-9-18-41)36(53)49-33(40(57)58)21-26-12-6-3-7-13-26/h2-7,10-13,23-24,28-33H,8-9,14-22,41-42H2,1H3,(H,43,44)(H,45,52)(H,46,55)(H,47,56)(H,48,54)(H,49,53)(H,50,51)(H,57,58)/t28-,29+,30-,31-,32-,33-/m0/s1
|
|||
| InChIKey |
QUCFVNGGGFLOES-ACQYNFKHSA-N
|
|||
| CAS Number |
CAS 50913-82-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Low-affinity nerve growth factor receptor (NGFR) | Target Info | Modulator | [2] |
| KEGG Pathway | Ras signaling pathway | |||
| Rap1 signaling pathway | ||||
| Cytokine-cytokine receptor interaction | ||||
| PI3K-Akt signaling pathway | ||||
| Neurotrophin signaling pathway | ||||
| Transcriptional misregulation in cancer | ||||
| Pathway Interaction Database | p75(NTR)-mediated signaling | |||
| Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Axonal growth inhibition (RHOA activation) | |||
| NRAGE signals death through JNK | ||||
| p75NTR negatively regulates cell cycle via SC1 | ||||
| Regulated proteolysis of p75NTR | ||||
| NADE modulates death signalling | ||||
| NRIF signals cell death from the nucleus | ||||
| p75NTR recruits signalling complexes | ||||
| NF-kB is activated and signals survival | ||||
| Axonal growth stimulation | ||||
| WikiPathways | Spinal Cord Injury | |||
| BDNF signaling pathway | ||||
| Signalling by NGF | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000019) | |||
| REF 2 | Effects of the ACTH4-9 analog Org2766 on brain plasticity: modulation of excitatory neurotransmission. Psychoneuroendocrinology. 1992 Aug;17(4):315-25. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.